AllianceBernstein
VRCA icon

AllianceBernstein’s Verrica Pharmaceuticals VRCA Stock Holding History

AllianceBernstein’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,220
Closed -$5.39K – 3342
2025
Q1 		$5.39K Hold
1,220
– – ﹤0.01% 3195
2024
Q4 		$8.54K Hold
1,220
– – ﹤0.01% 3220
2024
Q3 		$17.7K Hold
1,220
– – ﹤0.01% 3222
2024
Q2 		$88.9K Buy
+1,220
New +$93.7K ﹤0.01% 3130
2022
Q2 		– Sell
-1,910
Closed -$155K – 3389
2022
Q1 		$155K Hold
1,910
– – ﹤0.01% 3046
2021
Q4 		$175K Hold
1,910
– – ﹤0.01% 3110
2021
Q3 		$239K Hold
1,910
– – ﹤0.01% 3036
2021
Q2 		$216K Buy
1,910
+140
+8% +$17K ﹤0.01% 3133
2021
Q1 		$268K Hold
1,770
– – ﹤0.01% 2951
2020
Q4 		$204K Hold
1,770
– – ﹤0.01% 2989
2020
Q3 		$137K Hold
1,770
– – ﹤0.01% 3028
2020
Q2 		$195K Buy
1,770
+430
+32% +$49.7K ﹤0.01% 3010
2020
Q1 		$146K Buy
1,340
+330
+33% +$43.4K ﹤0.01% 2881
2019
Q4 		$160K Buy
+1,010
New +$149K ﹤0.01% 2968

Other funds holding VRCA

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SA
Sovran Advisors San Diego, California $1.34B AUM 21.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $95.2B AUM 32.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AllianceBernstein's VRCA Position: Q2 2025 in Review

AllianceBernstein sold out of Verrica Pharmaceuticals (VRCA) in Q2 2025, closing a stake of 1,220 shares — an estimated $5.39K sold.

AllianceBernstein first reported a position in VRCA in Q4 2019 and held it in 14 quarters. The position peaked at $268K in Q1 2021. 58 funds tracked by Wall St. Rank hold VRCA as of Q2 2025.

  • AllianceBernstein reported no remaining Verrica Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • AllianceBernstein sold 1,220 Verrica Pharmaceuticals shares in Q2 2025, an estimated $5.39K.
  • AllianceBernstein first reported a position in Verrica Pharmaceuticals in Q4 2019 and held it in 14 quarters.
  • AllianceBernstein's Verrica Pharmaceuticals position peaked at $268K in Q1 2021.
  • 58 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2025.

Based on AllianceBernstein's 13F filing for Q2 2025, filed 14 Aug 2025.